DC
EIGR

Davenport & Co’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Davenport & Co’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,957
Closed -$147K – 1101
2023
Q2 		$147K Sell
6,957
-766
-10% -$23.6K ﹤0.01% 1017
2023
Q1 		$208K Sell
7,723
-134
-2% -$6.23K ﹤0.01% 975
2022
Q4 		$278K Sell
7,857
-563
-7% -$67.6K ﹤0.01% 850
2022
Q3 		$1.9M Buy
8,420
+923
+12% +$227K 0.02% 365
2022
Q2 		$1.42M Sell
7,497
-156
-2% -$31.4K 0.01% 426
2022
Q1 		$1.91M Sell
7,653
-217
-3% -$34.3K 0.01% 402
2021
Q4 		$1.23M Sell
7,870
-4,713
-37% -$911K 0.01% 518
2021
Q3 		$2.52M Buy
12,583
+3,390
+37% +$806K 0.02% 345
2021
Q2 		$2.35M Sell
9,193
-224
-2% -$55.9K 0.02% 309
2021
Q1 		$2.5M Buy
9,417
+100
+1% +$31.5K 0.02% 258
2020
Q4 		$3.44M Buy
9,317
+1,614
+21% +$463K 0.03% 215
2020
Q3 		$1.88M Sell
7,703
-415
-5% -$129K 0.02% 253
2020
Q2 		$2.34M Sell
8,118
-167
-2% -$49.2K 0.03% 219
2020
Q1 		$1.69M Sell
8,285
-192
-2% -$61.2K 0.02% 231
2019
Q4 		$3.79M Buy
+8,477
New +$3.01M 0.04% 192

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Davenport & Co's EIGR Position: Q3 2023 in Review

Davenport & Co sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 6,957 shares — an estimated $147K sold.

Davenport & Co first reported a position in EIGR in Q4 2019 and held it in 15 quarters. The position peaked at $3.79M in Q4 2019. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.

  • Davenport & Co reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Davenport & Co sold 6,957 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $147K.
  • Davenport & Co first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2019 and held it in 15 quarters.
  • Davenport & Co's Eiger BioPharmaceuticals, Inc. position peaked at $3.79M in Q4 2019.
  • 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.

Based on Davenport & Co's 13F filing for Q3 2023, filed 17 Oct 2023.